Medtronic plc (MDT) EV/Sales Ratio: 3.44x
Is Medtronic plc’s EV/Sales ratio high or low?
Medtronic plc's EV/Sales ratio of 3.44x is 24% below its 5-year average of 4.55x, near the low end of its 5-year range (3.44x–7.06x).
The EV/Sales ratio for Medtronic plc (MDT) is 3.44x as of Wednesday, June 10, 2026. It is below its 12-month average by 18.37% (4.21x).
MDT EV/Sales Ratio Chart
MDT Average EV/Sales Ratio Chart
MDT Current vs Average EV/Sales Ratio Chart
MDT EV/Sales Ratio Metrics
EV/SALES RATIO
3.44x
EV/SALES RATIO AVG TTM
4.21x
EV/SALES RATIO AVG 3Y
4.19x
EV/SALES RATIO AVG 5Y
4.55x
EV/SALES RATIO AVG 10Y
4.86x
EV/SALES RATIO AVG 15Y
4.62x
EV/SALES RATIO AVG 20Y
4.49x
CURRENT VS TTM AVG
-18.37%
CURRENT VS 3Y AVG
-17.98%
CURRENT VS 5Y AVG
-24.34%
CURRENT VS 10Y AVG
-29.18%
CURRENT VS 15Y AVG
-25.61%
CURRENT VS 20Y AVG
-23.34%
MDT Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medtronic plc (MDT) | — | 3.44x | 4.21x | 4.19x | 4.55x |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 8.85x | 9.44x | 10.00x | 9.07x |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 3.08x | 2.99x | 3.12x | 3.48x |
| Elevance Health Inc. (ELV) | $87.43B | 0.55x | 0.51x | 0.67x | 0.76x |
| CVS Health Corporation (CVS) | $125.16B | 0.48x | 0.44x | 0.43x | 0.51x |
| Cigna Corporation (CI) | $78.25B | 0.37x | 0.38x | 0.50x | 0.55x |
| Danaher Corporation (DHR) | $130.25B | 5.81x | 6.63x | 7.16x | 7.00x |
| Regeneron Pharmaceuticals, Inc. (REGN) | $62.59B | 4.37x | 5.03x | 6.57x | 6.20x |
| Pfizer Inc. (PFE) | $146.36B | 3.31x | 3.30x | 3.43x | 3.63x |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 13.87x | 18.43x | 19.52x | 18.69x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Medtronic plc EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medtronic plc EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Medtronic plc (MDT)?
- The EV/Sales ratio for MDT stock is 3.44x.
- Is Medtronic plc's EV/Sales ratio high or low?
- Medtronic plc's EV/Sales ratio of 3.44x is 24% below its 5-year average of 4.55x, near the low end of its 5-year range (3.44x–7.06x).
- What is the TTM average EV/Sales ratio for Medtronic plc (MDT)?
- The TTM average EV/Sales ratio for MDT stock is 4.21x.
- What is the 3Y average EV/Sales ratio for Medtronic plc (MDT)?
- The 3Y average EV/Sales ratio for MDT stock is 4.19x.
- What is the 5Y average EV/Sales ratio for Medtronic plc (MDT)?
- The 5Y average EV/Sales ratio for MDT stock is 4.55x.
- What is the 10Y average EV/Sales ratio for Medtronic plc (MDT)?
- The 10Y average EV/Sales ratio for MDT stock is 4.86x.
- What is the 15Y average EV/Sales ratio for Medtronic plc (MDT)?
- The 15Y average EV/Sales ratio for MDT stock is 4.62x.
- What is the 20Y average EV/Sales ratio for Medtronic plc (MDT)?
- The 20Y average EV/Sales ratio for MDT stock is 4.49x.
Medtronic plc EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-02 | 3.44x |
| 2026-06-01 | 3.44x |
| 2026-05-29 | 3.44x |
| 2026-05-28 | 3.50x |
| 2026-05-27 | 3.52x |
| 2026-05-26 | 3.58x |
| 2026-05-22 | 3.61x |
| 2026-05-21 | 3.60x |
| 2026-05-20 | 3.60x |
| 2026-05-19 | 3.61x |
| 2026-05-18 | 3.57x |
| 2026-05-15 | 3.52x |
| 2026-05-14 | 3.55x |
| 2026-05-13 | 3.53x |
| 2026-05-12 | 3.55x |
| 2026-05-11 | 3.46x |
| 2026-05-08 | 3.52x |
| 2026-05-07 | 3.59x |
| 2026-05-06 | 3.58x |
| 2026-05-05 | 3.58x |
| 2026-05-04 | 3.60x |
| 2026-05-01 | 3.66x |
| 2026-04-30 | 3.70x |
| 2026-04-29 | 3.64x |
| 2026-04-28 | 3.73x |
| 2026-04-27 | 3.77x |
| 2026-04-24 | 3.78x |
| 2026-04-23 | 3.80x |
| 2026-04-22 | 3.78x |
| 2026-04-21 | 3.74x |
| 2026-04-20 | 3.84x |
| 2026-04-17 | 3.89x |
| 2026-04-16 | 3.87x |
| 2026-04-15 | 3.92x |
| 2026-04-14 | 3.96x |
| 2026-04-13 | 3.95x |
| 2026-04-10 | 3.92x |
| 2026-04-09 | 3.95x |
| 2026-04-08 | 3.98x |
| 2026-04-07 | 3.90x |
| 2026-04-06 | 3.89x |
| 2026-04-02 | 3.90x |
| 2026-04-01 | 3.88x |
| 2026-03-31 | 3.90x |
| 2026-03-30 | 3.87x |
| 2026-03-27 | 3.92x |
| 2026-03-26 | 3.94x |
| 2026-03-25 | 3.95x |
| 2026-03-24 | 3.90x |
| 2026-03-23 | 3.92x |
| 2026-03-20 | 3.89x |
| 2026-03-19 | 3.91x |
| 2026-03-18 | 3.92x |
| 2026-03-17 | 3.97x |
| 2026-03-16 | 3.96x |
| 2026-03-13 | 3.92x |
| 2026-03-12 | 3.93x |
| 2026-03-11 | 3.99x |
| 2026-03-10 | 4.02x |
| 2026-03-09 | 4.07x |
| 2026-03-06 | 4.06x |
| 2026-03-05 | 4.14x |
| 2026-03-04 | 4.23x |
| 2026-03-03 | 4.27x |
| 2026-03-02 | 4.32x |
| 2026-02-27 | 4.30x |
| 2026-02-26 | 4.28x |
| 2026-02-25 | 4.27x |
| 2026-02-24 | 4.27x |
| 2026-02-23 | 4.45x |
| 2026-02-20 | 4.39x |
| 2026-02-19 | 4.41x |
| 2026-02-18 | 4.45x |
| 2026-02-17 | 4.37x |
| 2026-02-13 | 4.49x |
| 2026-02-12 | 4.54x |
| 2026-02-11 | 4.54x |
| 2026-02-10 | 4.56x |
| 2026-02-09 | 4.57x |
| 2026-02-06 | 4.61x |
| 2026-02-05 | 4.61x |
| 2026-02-04 | 4.57x |
| 2026-02-03 | 4.62x |
| 2026-02-02 | 4.60x |
| 2026-01-30 | 4.61x |
| 2026-01-29 | 4.54x |
| 2026-01-28 | 4.53x |
| 2026-01-27 | 4.53x |
| 2026-01-26 | 4.53x |
| 2026-01-23 | 4.54x |
| 2026-01-22 | 4.55x |
| 2026-01-21 | 4.52x |
| 2026-01-20 | 4.45x |
| 2026-01-16 | 4.38x |
| 2026-01-15 | 4.47x |
| 2026-01-14 | 4.46x |
| 2026-01-13 | 4.37x |
| 2026-01-12 | 4.39x |
| 2026-01-09 | 4.41x |
| 2026-01-08 | 4.46x |
| 2026-01-07 | 4.50x |
| 2026-01-06 | 4.52x |
| 2026-01-05 | 4.41x |
| 2026-01-02 | 4.36x |
| 2025-12-31 | 4.36x |
| 2025-12-30 | 4.38x |
| 2025-12-29 | 4.36x |
| 2025-12-26 | 4.38x |
| 2025-12-24 | 4.40x |
| 2025-12-23 | 4.41x |
| 2025-12-22 | 4.42x |
| 2025-12-19 | 4.45x |
| 2025-12-18 | 4.45x |
| 2025-12-17 | 4.44x |
| 2025-12-16 | 4.42x |
| 2025-12-15 | 4.45x |
| 2025-12-12 | 4.50x |
| 2025-12-11 | 4.50x |
| 2025-12-10 | 4.53x |
| 2025-12-09 | 4.49x |
| 2025-12-08 | 4.55x |
| 2025-12-05 | 4.55x |
| 2025-12-04 | 4.58x |
| 2025-12-03 | 4.58x |
| 2025-12-02 | 4.58x |
| 2025-12-01 | 4.63x |
| 2025-11-28 | 4.70x |
| 2025-11-26 | 4.69x |
| 2025-11-25 | 4.70x |
| 2025-11-24 | 4.68x |
| 2025-11-21 | 4.61x |
| 2025-11-20 | 4.54x |
| 2025-11-19 | 4.58x |
| 2025-11-18 | 4.59x |
| 2025-11-17 | 4.42x |
| 2025-11-14 | 4.41x |
| 2025-11-13 | 4.42x |
| 2025-11-12 | 4.41x |
| 2025-11-11 | 4.39x |
| 2025-11-10 | 4.29x |
| 2025-11-07 | 4.27x |
| 2025-11-06 | 4.19x |
| 2025-11-05 | 4.20x |
| 2025-11-04 | 4.20x |
| 2025-11-03 | 4.19x |
| 2025-10-31 | 4.21x |
| 2025-10-30 | 4.22x |
| 2025-10-29 | 4.25x |
| 2025-10-28 | 4.31x |
| 2025-10-27 | 4.34x |
| 2025-10-24 | 4.32x |
| 2025-10-23 | 4.34x |
| 2025-10-22 | 4.41x |
| 2025-10-21 | 4.41x |
| 2025-10-20 | 4.41x |
| 2025-10-17 | 4.40x |
| 2025-10-16 | 4.38x |
| 2025-10-15 | 4.39x |
| 2025-10-14 | 4.43x |
| 2025-10-13 | 4.40x |
| 2025-10-10 | 4.39x |
| 2025-10-09 | 4.43x |
| 2025-10-08 | 4.48x |
| 2025-10-07 | 4.50x |
| 2025-10-06 | 4.50x |
| 2025-10-03 | 4.48x |
| 2025-10-02 | 4.39x |
| 2025-10-01 | 4.37x |
| 2025-09-30 | 4.38x |
| 2025-09-29 | 4.34x |
| 2025-09-26 | 4.35x |
| 2025-09-25 | 4.35x |
| 2025-09-24 | 4.40x |
| 2025-09-23 | 4.37x |
| 2025-09-22 | 4.36x |
| 2025-09-19 | 4.38x |
| 2025-09-18 | 4.40x |
| 2025-09-17 | 4.36x |
| 2025-09-16 | 4.34x |
| 2025-09-15 | 4.32x |
| 2025-09-12 | 4.34x |
| 2025-09-11 | 4.35x |
| 2025-09-10 | 4.27x |
| 2025-09-09 | 4.34x |
| 2025-09-08 | 4.30x |
| 2025-09-05 | 4.30x |
| 2025-09-04 | 4.29x |
| 2025-09-03 | 4.27x |
| 2025-09-02 | 4.31x |
| 2025-08-29 | 4.29x |
| 2025-08-28 | 4.26x |
| 2025-08-27 | 4.26x |
| 2025-08-26 | 4.27x |
| 2025-08-25 | 4.32x |
| 2025-08-22 | 4.34x |
| 2025-08-21 | 4.28x |
| 2025-08-20 | 4.36x |
| 2025-08-19 | 4.24x |
| 2025-08-18 | 4.35x |
| 2025-08-15 | 4.36x |
| 2025-08-14 | 4.32x |
| 2025-08-13 | 4.35x |
| 2025-08-12 | 4.32x |
| 2025-08-11 | 4.35x |
| 2025-08-08 | 4.35x |
| 2025-08-07 | 4.29x |
| 2025-08-06 | 4.22x |
| 2025-08-05 | 4.23x |
| 2025-08-04 | 4.23x |
| 2025-08-01 | 4.21x |
| 2025-07-31 | 4.25x |
| 2025-07-30 | 4.30x |
| 2025-07-29 | 4.33x |
| 2025-07-28 | 4.32x |
| 2025-07-25 | 4.35x |
| 2025-07-24 | 4.33x |
| 2025-07-23 | 4.32x |
| 2025-07-22 | 4.30x |
| 2025-07-21 | 4.23x |
| 2025-07-18 | 4.22x |
| 2025-07-17 | 4.22x |
| 2025-07-16 | 4.23x |
| 2025-07-15 | 4.21x |
| 2025-07-14 | 4.23x |
| 2025-07-11 | 4.24x |
| 2025-07-10 | 4.22x |
| 2025-07-09 | 4.20x |
| 2025-07-08 | 4.19x |
| 2025-07-07 | 4.15x |
| 2025-07-03 | 4.18x |
| 2025-07-02 | 4.17x |
| 2025-07-01 | 4.19x |
| 2025-06-30 | 4.13x |
| 2025-06-27 | 4.09x |
| 2025-06-26 | 4.09x |
| 2025-06-25 | 4.09x |
| 2025-06-24 | 4.09x |
| 2025-06-23 | 4.08x |
| 2025-06-20 | 4.10x |
| 2025-06-18 | 4.09x |
| 2025-06-17 | 4.10x |
| 2025-06-16 | 4.17x |
| 2025-06-13 | 4.15x |
| 2025-06-12 | 4.19x |
| 2025-06-11 | 4.18x |
| 2025-06-10 | 4.17x |
| 2025-06-09 | 4.15x |
| 2025-06-06 | 4.15x |
| 2025-06-05 | 4.13x |
| 2025-06-04 | 4.08x |
| 2025-06-03 | 4.08x |
| 2025-06-02 | 4.01x |
| 2025-05-30 | 3.98x |
| 2025-05-29 | 3.96x |
| 2025-05-28 | 3.91x |
| 2025-05-27 | 3.91x |
| 2025-05-23 | 3.89x |
| 2025-05-22 | 3.90x |
| 2025-05-21 | 4.03x |
| 2025-05-20 | 4.11x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Medtronic plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha